Utah Medical Products (NASDAQ:UTMD) Stock: Insider Kevin Cornwell Buys 1,000 Shares

Utah Medical Products, Inc. (NASDAQ:UTMD) CEO Kevin Cornwell bought 1,000 shares of the stock in a transaction dated Thursday, October 29th. The shares were acquired at an average price of $66.75 per share, for a total transaction of $66,750.00. Following the completion of the transaction, the chief executive officer owned 189,472 shares of the company’s stock, valued at approximately $12,647,256. The trade was a 0.53% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Utah Medical Products Price Performance

Shares of NASDAQ:UTMD opened at $68.07 on Friday. Utah Medical Products, Inc. has a 1-year low of $53.66 and a 1-year high of $76.89. The stock has a market cap of $216.46 million, a P/E ratio of 20.00 and a beta of 0.38. The firm has a fifty day moving average price of $72.90 and a 200 day moving average price of $68.01.

Utah Medical Products (NASDAQ:UTMD) last announced its earnings results on Thursday, October 22nd. The medical instruments supplier reported $0.88 earnings per share for the quarter. The business had revenue of $8.62 million during the quarter. Utah Medical Products had a net margin of 30.48% and a return on equity of 8.83%.

Utah Medical Products Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, October 5th. Shareholders of record on Thursday, September 17th were issued a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend was Thursday, September 17th. Utah Medical Products’s payout ratio is currently 37.13%.

Institutional Investors Weigh In On Utah Medical Products

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Utah Medical Products during the second quarter valued at $14,051,000. Rice Hall James & Associates LLC acquired a new position in shares of Utah Medical Products in the second quarter valued at approximately $4,923,000. Bank of New York Mellon Corp purchased a new position in shares of Utah Medical Products during the second quarter valued at approximately $2,363,000. Bard Associates Inc. acquired a new stake in Utah Medical Products during the second quarter worth approximately $1,279,000. Finally, Segall Bryant & Hamill LLC raised its holdings in Utah Medical Products by 87.7% in the 1st quarter. Segall Bryant & Hamill LLC now owns 21,547 shares of the medical instruments supplier’s stock valued at $1,336,000 after acquiring an additional 10,065 shares during the last quarter. Institutional investors and hedge funds own 69.60% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Utah Medical Products from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Hold rating. According to MarketBeat, the company currently has a consensus rating of “Hold”.

Utah Medical Products Company Profile

Utah Medical Products, Inc (NASDAQ:UTMD) develops, manufactures and distributes medical devices used primarily in hospital and clinical settings. The company focuses on specialized products for women’s health, childbirth, neonatal care, electrosurgery, gastroenterology and related medical applications.

Its product portfolio includes fetal monitoring electrodes and catheters, intrauterine pressure monitoring devices, vacuum-assisted delivery systems, neonatal respiratory and care products, electrosurgical accessories, and other disposable and specialty medical instruments.